MwanzoDBV • EPA
add
DBV Technologies SA
Bei iliyotangulia
€ 2.62
Bei za siku
€ 2.48 - € 2.60
Bei za mwaka
€ 0.51 - € 3.19
Thamani ya kampuni katika soko
438.34M EUR
Wastani wa hisa zilizouzwa
1.41M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
EPA
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 2.77M | 158.77% |
Matumizi ya uendeshaji wa biashara | 37.05M | 18.00% |
Mapato halisi | -33.16M | -8.94% |
Kiwango cha faida halisi | elfu -1.20 | 57.90% |
Mapato kwa kila hisa | -0.21 | 86.19% |
EBITDA | -33.49M | — |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 69.84M | 50.38% |
Jumla ya mali | 110.50M | 18.74% |
Jumla ya dhima | 57.64M | 47.72% |
Jumla ya hisa | 52.85M | — |
hisa zilizosalia | 168.95M | — |
Uwiano wa bei na thamani | 6.71 | — |
Faida inayotokana na mali | -67.50% | — |
Faida inayotokana mtaji | -110.96% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -33.16M | -8.94% |
Pesa kutokana na shughuli | -32.44M | -44.43% |
Pesa kutokana na uwekezaji | elfu -241.00 | -121.10% |
Pesa kutokana na ufadhili | elfu 130.00 | 1,757.14% |
Mabadiliko halisi ya pesa taslimu | -33.37M | -68.79% |
Mtiririko huru wa pesa | -21.19M | -62.74% |
Kuhusu
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
Ilianzishwa
29 Mac 2002
Tovuti
Wafanyakazi
117
